latuda 37 mg
orifarm as - lurasidonhydroklorid - tablett, filmdrasjert - 37 mg
latuda 37 mg
2care4 aps - lurasidonhydroklorid - tablett, filmdrasjert - 37 mg
latuda 74 mg
2care4 aps - lurasidonhydroklorid - tablett, filmdrasjert - 74 mg
tukysa
seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - antineoplastiske midler - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.
terbinafin bluefish 250 mg
bluefish pharmaceuticals ab - terbinafinhydroklorid - tablett - 250 mg
terbinafin hexal 250 mg
hexal a/s - terbinafinhydroklorid - tablett - 250 mg
lamisil 1 % w/w
karo healthcare ab - terbinafinhydroklorid - liniment, oppløsning - 1 % w/w
onytec 80 mg/ g
polichem sa - ciklopiroks - medisinsk neglelakk - 80 mg/ g
terbinafin hexal 10 mg/ g
hexal a/s - terbinafinhydroklorid - krem - 10 mg/ g